特点 Feature | 说明 Description | 客户价值 Value |
First-in-Class Non-Opioid Analgesic 首创非阿片类镇痛药 | First FDA-approved intrathecal analgesic that works through a non-opioid mechanism by selectively blocking N-type calcium channels (Cav2.2) in the spinal cord. 首个FDA批准的通过非阿片类机制发挥作用的鞘内镇痛药，选择性阻断脊髓中N型钙通道（Cav2.2）。 | No risk of respiratory depression, opioid-induced hyperalgesia, tolerance development, or addiction - addressing critical unmet needs in chronic pain management. 无呼吸抑制、阿片诱导痛觉过敏、耐受性或成瘾风险 - 满足慢性疼痛管理中的关键未满足需求。 |
Potent & Selective Action 强效选择性作用 | Three disulfide bridges stabilize the conformation for high-affinity binding to Cav2.2 channels, providing potent analgesia at nanomolar concentrations. 三个二硫键稳定构象，以高亲和力结合Cav2.2通道，在纳摩尔浓度下提供强效镇痛。 | Superior pain relief for patients with neuropathic pain, cancer pain, and opioid-refractory conditions. 对神经病理性疼痛、癌痛和阿片类药物难治性病症患者的疼痛缓解效果优异。 |
No CNS Side Effects 无中枢副作用 | Intrathecal delivery bypasses systemic circulation, minimizing central nervous system and systemic adverse effects common with oral/systemic analgesics. 鞘内给药绕过全身循环，最大限度地减少口服/全身镇痛药常见的中枢神经系统和全身不良反应。 | Improved patient quality of life and compliance compared to systemic opioid therapy with equivalent or superior efficacy. 与全身阿片类药物治疗相比，疗效相当或更优，患者生活质量和依从性得到改善。 |
Complex Peptide Manufacturing 复杂肽合成能力 | 25-amino acid peptide with three critical disulfide bridges requires advanced synthetic expertise; supplied at >=98.0% purity with full analytical documentation. 含三个关键二硫键的25氨基酸肽需要先进合成技术；提供>=98.0%纯度及完整分析文件。 | Access to a rare and technically challenging API backed by validated synthesis and quality control processes. 获得稀有且技术要求高的API，以经过验证的合成和质量控制流程为后盾。 |
Complete Regulatory Package 完整法规包 | Comprehensive CMC documentation including detailed synthetic route, impurity profile, and stability data for global registration support. 全面的CMC文件，包括详细合成路线、杂质谱和稳定性数据，支持全球注册。 | Accelerated market entry for generic developers and formulation partners targeting chronic pain therapeutics. 加速仿制药开发商和制剂合作伙伴进入慢性疼痛治疗市场。 |
Scalable Supply 可扩展供应 | Production capacity from gram-scale for R&D to kilogram-scale for commercial supply, with consistent batch-to-batch quality. 从克级研发到公斤级商业供应的生产能力，批次间质量一致。 | Supports seamless transition from clinical trials to commercial launch with reliable supply chain planning. 支持从临床试验到商业上市的平稳过渡，供应链规划可靠。 |
End-to-End Procurement 端到端采购 | Single-source supply of API, reference standards, stability-indicating methods, and regulatory submission packages. API、对照品、稳定性指示方法和法规申报包的单一来源供应。 | Reduces procurement complexity and ensures full traceability from synthesis to final delivery. 降低采购复杂性，确保从合成到最终交付的完整可追溯性。 |